Anifrolumab
Adding anifrolumab superior to standard therapy alone, maintains remission in lupus
Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity and remission, and more time spent in those states, vs. standard therapy alone, according to data.
Uptake of Benlysta, Saphnelo signal ‘exciting time’ for ‘lupologists’
Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.
Understanding lupus processes helps identify ‘important targets’ for intervention
Ongoing research into the disease processes of lupus has yielded an increased number of therapeutic targets, according to a presenter at the 2024 Association of Women in Rheumatology annual conference.
'Choose wisely': Each biologic for lupus has 'ideal patient profile'
DESTIN, Fla. — When choosing between biologic drugs for systemic lupus erythematosus, it is important to know the “ideal patient profile” each is best suited for, according to a speaker at the Congress of Clinical Rheumatology East.
‘Exciting time’: Biologic use in moderate to severe lupus rose 45% since 2021
Use of biologics to treat moderate to severe systemic lupus erythematosus increased 45% between 2021 and 2023, according to recent findings from a market analysis conducted by Spherix Global Insights.
Anifrolumab increases odds of earlier, sustained low disease activity vs placebo in lupus
Patients with systemic lupus erythematosus receiving anifrolumab are more likely to achieve earlier, more frequent and longer low disease activity, compared with those taking placebo, according to data.
Trio of anifrolumab lupus trials show concordant BICLA, SRI(4) responses in most patients
Most patients with systemic lupus erythematosus across a trio of anifrolumab trials demonstrated concordant outcomes on BILAG-based Composite Lupus Assessment and SLE Responder Index responses, according to data.
Anifrolumab reduces lupus disease activity across musculoskeletal, mucocutaneous domains
Anifrolumab improves systemic lupus erythematosus disease activity across musculoskeletal, mucocutaneous and immunological domains, according to a post-hoc analysis of TULIP-1 and TULIP-2 data published in The Lancet Rheumatology.
TULIP: Anifrolumab superior to standard of care for lupus regardless of prior biologic use
A 300-mg dose of anifrolumab provided clinically meaningful benefit and was generally well-tolerated among patients with systemic lupus erythematosus, regardless of previous exposure to biologic agents, according to data presented at ACR Convergence 2021.
Top in rheumatology: New lupus drug, telehealth preferences
The FDA recently approved the first new drug for systemic lupus erythematosus since 2011. It was the top story in rheumatology last week.